Dr. Weber on Discontinuing Immunotherapy in Melanoma

Video

In Partnership With:

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

In early studies involving pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq), patients were treated until progression, Weber says. In melanoma, 15% to 20% of patients are in remission for 3 to 6 years, so treating them until progression is not rational. Questions of duration now arise, but reasoning for discontinuation is not yet established.

Weber says that in reviewing retrospective data, there are some hints of how long patients with melanoma should be treated. In the KEYNOTE-006 trial, patients were randomized to pembrolizumab versus ipilimumab (Yervoy) in the frontline setting. Data show that patients who received a complete or partial response and went off therapy at 2 years did extremely well, Weber says. The remaining rate of remission in those patients was around 90%. The bottom line, he states, is that it is safe to stop immunotherapy at 2 years in some patients with melanoma. This analysis could potentially be extrapolated to lung, bladder, and head and neck cancer.

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB